Abstract
The recent report from the Institute of Medicine on the US systems for ensuring drug safety emphasized deficiencies in post-approval assessment of drug risks. As the drug safety debate progresses, the importance of assessing drug risks and benefits together should not be forgotten, and nor should the harm that can be caused by undue delay of new therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
